Zoetis Inc. $ZTS Shares Sold by Griffin Asset Management Inc.

Griffin Asset Management Inc. decreased its position in Zoetis Inc. (NYSE:ZTS) by 0.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,908 shares of the company’s stock after selling 204 shares during the quarter. Griffin Asset Management Inc.’s holdings in Zoetis were worth $5,132,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. acquired a new stake in Zoetis in the first quarter valued at approximately $25,000. 1248 Management LLC acquired a new stake in Zoetis in the first quarter valued at approximately $27,000. Saudi Central Bank purchased a new position in Zoetis in the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC increased its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC increased its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $141.05 on Monday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm has a market cap of $62.51 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.26 and a beta of 0.90. The company’s 50 day simple moving average is $149.24 and its 200-day simple moving average is $154.33. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period last year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Analyst Upgrades and Downgrades

Several brokerages have commented on ZTS. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Argus reiterated a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $196.71.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.